Actually,  ACST’s studies show that CaPre has neutral to beneficial effects on LDL.

Additionally, it does not need to be taken with a fatty meal.

Your other points are well taken.

However, they are financed and will, as you mention, ride the coat tails of AMRN.

AMRN market cap is almost $7 Billion.

ACST is at $85 million.

The latter may turn out to have the better drive down the road.

bfw